There was no activity above background observed for any of the cancer cells treated with EDC-FAP or EDC-HER2 (EC50 >100,000 pmol/l), even though the presence of both targets was confirmed via live cell antibody staining and CG1 sensitivity. This evidence concerns the gene FAP and cancer.